Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-029: Pembrolizumab Combinations in Advanced Melanoma and RCC
NCT02089685Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma and renal cell carcinoma (RCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Dose-limiting Toxicities at 6 weeks, Percentage of Participants Experiencing Adverse Events at 84 months and 5 more. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02089685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089685.